Treatment of pulmonary arterial hypertension

Jornal de Pediatria

Volumn 82, Issue SUPPL. 2, 2006, Pages

  Ricachinevsky, Cláudia Pires ^a,b   Amantéa, Sérgio Luís ^a,c,d  

^a HOSPITAL DA CRIANÇA SANTO ANTÔNIO   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d NONE   (Brazil)

Author keywords

Bosentan; Nitric oxide; Pulmonary arterial hypertension; Pulmonary hypertension; Sildenafil

Indexed keywords

AMBRISENTAN; AMLODIPINE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CLOPIDOGREL; DIGITALIS; DIPYRIDAMOLE; DIURETIC AGENT; HEPARIN; ILOPROST; NIFEDIPINE; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TEPROSTINIL; TICLOPIDINE; VASODILATOR AGENT; WARFARIN;

BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COUGHING; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; DRUG POTENTIATION; ECHOCARDIOGRAPHY; ERYTHEMA; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; LABORATORY TEST; LEG PAIN; LUNG ANGIOGRAPHY; LUNG BIOPSY; LUNG FUNCTION TEST; MEDLINE; MORTALITY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PAIN; PALLIATIVE THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PENILE PAIN; PENIS ERECTION; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYPHYLAXIS; TERATOGENESIS; THORAX RADIOGRAPHY;

ANTIHYPERTENSIVE AGENTS; CHILD; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROGNOSIS; PURINES; RECEPTORS, ENDOTHELIN; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; SULFONES;

EID: 33845748289     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1556     Document Type: Review

References (77)

1. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004;125:580-6.
2. Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician. 2001;63:1789-98.
3. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J. 2003;21:155-76.
4. Budev MM, Arroliga AC, Jennings CA. Diagnosis and evaluation of pulmonary hypertension. Cleve Clin J Med. 2003;70 Suppl 1:S9-17.
5. Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pediatr Clin North Am. 1999;46:331-45.
6. Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol. 2004;38:2-22.
7. Tulloh RM. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev. 2005;6:174-80.
8. Lang IM, Bonderman D, Kneussl M, Marx M. Paediatric pulmonary vascular disease. Paediatr Resp Rev. 2004;5:238-48.
9. Rich S, editor. Primary pulmonary hypertension: executive summary from the World Symposium-Primary Pulmonary Hypertension 1998. http://www.who.int/ncd/ dvd/pph.html Access: 02/09/2006.
10. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
11. Kanthapillai P, Lasserson TJ, Walters EH. Sildenafil for pulmonary hypertension. (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software. 2005.
12. Gozal D, O'Brien LM. Snoring and obstructive sleep apnoea in children: why should we treat? Paediatr Respir Rev. 2004;5 Suppl A):S371-6.
13. Blum RH, McGowan FX Jr. Chronic upper airway obstruction and cardiac dysfunction: anatomy pathophysiology and anesthetic implications. Pediatric Anaesth. 2004;14:75-83.
14. Berger M, Haimowitz A, Van Tosh A, Berdorff RL, Golberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6:359-65.
15. Chockalingam A, Gnanavelu G, Venkatesan S, Elangovan S, Jagannathan V, Subramaniam T, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol. 2005;99:91-5.
16. Homma A, Anzueto A, Peters JI, Susanto I, Sako E, Zabalgoitia M, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs. cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant. 2001;20:833-9.
17. Khan MG. Pulmonary hypertension and cor pulmonale. In: Khan MG, Lynch JP III, eds. Pulmonary disease diagnosis and therapy: a practical approach. Baltimore: Williams & Wilkins; 1997. p. 603-16.
18. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-36.
19. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112:714-21.
20. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs. 2001;61:1945-56.
21. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
22. Sitbon O, Humbert M, Ioos V. Who benefits from long term calcium-channel blocker therapy in primary pulmonary hypertension? Am J Respir Crit Care Med. 2003;167:A440.
23. Christman BW, McPherson CD, Newmann JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Eng J Med. 1992;327:70-5.
24. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-32.
25. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-502.
26. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
27. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-34.
28. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-8.
29. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-82.
30. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J. 1999;13:1351-6.
31. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003;167:580-6.
32. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo controlled trial. Am J Respir Crit Care Med. 2002;165:800-4.
33. Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26:1895-902.
34. Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamani F, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1188-92.
35. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-70.
36. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372-82.
37. Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm. 2004;61:1107-19.
38. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of dual endothelin-receptor antagonist besentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet. 2001;358:1119-23.
39. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:1380-6.
40. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:697-704.
41. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest. 2002;121:1860-8.
42. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan, therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441-7.
43. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology. 1999;91:1090-121.
44. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn and role of inhaled nitric oxide: practice variation and outcomes. Pediatrics. 2000;105:14-20.
45. Goldman AP, Delius RE, Deanfield JE, Macrae DJ. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg. 1995;60:300-5.
46. Macrae DJ, Field D, Mercier JC, Moller J, Stiris T, Biban P, et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med. 2004;30:372-80.
47. Ng J, Finney SJ, Shulman R, Bellingan G J, Singer M, Glynne PA. Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil? Br J Anaesth. 2005;114:1-4.
48. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91:307-10.
49. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med. 2000;343:1342.
50. Bigatello LM, Hess D, Dennehy KC, Medoff BD, Hurford WE. Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology. 2000;92:1827-9.
51. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart. 2000;84:E4.
52. Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch KD, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology. 2000;92:1702-12.
53. Zhao L, Mason NA, Morrel NW, Kojonazarov B, Sadykov A, Maripov A, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-8.
54. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med. 2001;29:1000-5.
55. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med. 2002;165:1098-102.
56. Kleinsasser A, Loeckinger A, Hoermann C, Puehringer F, Mutz N, Bartsch G, et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med. 2001;163:339-43.
57. Cheitlin M, Hutter AM Jr., Brindis RG, Ganz P, Kaul S, Russell RO Jr., et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation. 1999;99:168-77.
58. Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med. 2004;5:184-7.
59. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-22.
60. Jimenez López-Guarch C, Escribano Subias P, Tello de Meneses R, Delgado Jimenez JF, Sadia Peres D, Velazquez Martin MT, et al. Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results. Rev Esp Cardiol. 2004;57:946-51.
61. Kataoka M, Satoh T, Manabe T, Anzai T, Yoshikawa T, Mitamura H, et al. Oral sildenafil improves primary hypertension refractory to epoprostenol. Circ J. 2005;69:461-5.
62. Ikeda D, Tsujino I, Ohira H, Itoh N, Kamigaki M, Ishimaru S, et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovasc Pharmacol. 2005;45:286-9.
63. Trachte AL, Lobato EB, Urdaneta F, Hess PJ, Klodell CT, Martin TD, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg. 2005;79:194-7.
64. Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hubler M, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003;108 Suppl 1:II167-73.
65. Bentlin MR, Saito A, De Luca AK, Bossolan G, Bonatto RC, Martins AS, et al. Sildenafil no tratamento da hipertensão pulmonar após cirurgia cardíaca. J Pediatr (Rio J). 2005;81:175-8.
66. Cantrell FL. Sildenafil citrate ingestion in a pediatric patient. Pediatr Emerg Care. 2004;20:314-5.
67. Clouzeau J, Paihle L, Rakotonirina G. Accidental ingestion of sildenafil (Viagra) by a child. Arch Pediatr. 1999;6:904
68. Marsh CS, Marden B, Newson R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol. 2004;88:306-7.
69. Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. Br J Ophthalmol. 2005;89:250.
70. Ricachinevsky CP, Amantea SL. Efeitos imediatos do sildenafil na hipertensão arterial pulmonar de pacientes pediátricos [dissertação]. Porto Alegre: Fundação Federal Faculdade Ciências Médicas de Porto Alegre; 2005.
71. Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary hypertension. Chest. 2003;123:1293-5.
72. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J. 2003;22:330-4.
73. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Baerst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91:2028-35.
74. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, et al. Graded balloon dilation atrial septostomy in severe primary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998;32:297-304.
75. Pasque MK, Trulock EP, Cooper JD, Triantafillou AN, Huddleston CB, Rosenbloom M, et al. Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. Circulation. 1995;92:2252-8.
76. Spray TL, Bridges ND. Lung transplantation for pediatric pulmonary hypertension. Prog Pediatr Cardiol. 2001;12:319-25.
77. Camargo JJ, Grupo de Transplante Pulmonar da Santa Casa de Porto Alegre, RS, Brasil. Transplante pulmonar na infância. J Pediatr (Rio J). 2002;78 Suppl. 2:S113-22.